213 related articles for article (PubMed ID: 28500232)
1. NKG2D Ligand-Targeted Bispecific T-Cell Engagers Lead to Robust Antitumor Activity against Diverse Human Tumors.
Godbersen C; Coupet TA; Huehls AM; Zhang T; Battles MB; Fisher JL; Ernstoff MS; Sentman CL
Mol Cancer Ther; 2017 Jul; 16(7):1335-1346. PubMed ID: 28500232
[TBL] [Abstract][Full Text] [Related]
2. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.
Zhang T; Sentman CL
Cancer Res; 2011 Mar; 71(6):2066-76. PubMed ID: 21282338
[TBL] [Abstract][Full Text] [Related]
3. Impaired tumor rejection by memory CD8 T cells in mice with NKG2D dysfunction.
André MC; Sigurdardottir D; Kuttruff S; Pömmerl B; Handgretinger R; Rammensee HG; Steinle A
Int J Cancer; 2012 Oct; 131(7):1601-10. PubMed ID: 21607945
[TBL] [Abstract][Full Text] [Related]
4. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.
Zhang T; Barber A; Sentman CL
Cancer Res; 2006 Jun; 66(11):5927-33. PubMed ID: 16740733
[TBL] [Abstract][Full Text] [Related]
5. TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors.
Maccalli C; Scaramuzza S; Parmiani G
Cancer Immunol Immunother; 2009 May; 58(5):801-8. PubMed ID: 19089424
[TBL] [Abstract][Full Text] [Related]
6. Detuning CD8+ T lymphocytes by down-regulation of the activating receptor NKG2D: role of NKG2D ligands released by activated T cells.
Cerboni C; Ardolino M; Santoni A; Zingoni A
Blood; 2009 Mar; 113(13):2955-64. PubMed ID: 19124832
[TBL] [Abstract][Full Text] [Related]
7. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.
Oberst MD; Fuhrmann S; Mulgrew K; Amann M; Cheng L; Lutterbuese P; Richman L; Coats S; Baeuerle PA; Hammond SA
MAbs; 2014; 6(6):1571-84. PubMed ID: 25484061
[TBL] [Abstract][Full Text] [Related]
8. NKG2D and Its Ligand MULT1 Contribute to Disease Progression in a Mouse Model of Multiple Sclerosis.
Legroux L; Moratalla AC; Laurent C; Deblois G; Verstraeten SL; Arbour N
Front Immunol; 2019; 10():154. PubMed ID: 30787931
[TBL] [Abstract][Full Text] [Related]
9. NKG2D ligand expression in Crohn's disease and NKG2D-dependent stimulation of CD8
Vadstrup K; Galsgaard ED; Jensen H; Lanier LL; Ryan JC; Chen SY; Nolan GP; Vester-Andersen MK; Pedersen JS; Gerwien J; Jensen T; Bendtsen F
Exp Mol Pathol; 2017 Aug; 103(1):56-70. PubMed ID: 28684217
[TBL] [Abstract][Full Text] [Related]
10. NK cell-mediated anti-leukemia cytotoxicity is enhanced using a NKG2D ligand MICA and anti-CD20 scfv chimeric protein.
Zou Y; Luo W; Guo J; Luo Q; Deng M; Lu Z; Fang Y; Zhang CC
Eur J Immunol; 2018 Oct; 48(10):1750-1763. PubMed ID: 30063799
[TBL] [Abstract][Full Text] [Related]
11. Production of a novel bispecific protein ULBP1×CD19-scFv targeting the NKG2D receptor and CD19 to promote the activation of NK cells.
Zhao Q; Pang J; Yan F; Jiang Y; Cui D; Liu J; Jing L; Li Y; Liu Z; Tao L; Zhao X; Diao A
Protein Expr Purif; 2021 Feb; 178():105783. PubMed ID: 33122138
[TBL] [Abstract][Full Text] [Related]
12. NKG2D receptor activation of NF-κB enhances inflammatory cytokine production in murine effector CD8(+) T cells.
Whitman E; Barber A
Mol Immunol; 2015 Feb; 63(2):268-78. PubMed ID: 25089028
[TBL] [Abstract][Full Text] [Related]
13. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
[TBL] [Abstract][Full Text] [Related]
14. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
[TBL] [Abstract][Full Text] [Related]
15. BCMA-targeting Bispecific Antibody That Simultaneously Stimulates NKG2D-enhanced Efficacy Against Multiple Myeloma.
Wang Y; Li H; Xu W; Pan M; Qiao C; Cai J; Xu J; Wang M; Zhang J
J Immunother; 2020; 43(6):175-188. PubMed ID: 32349046
[TBL] [Abstract][Full Text] [Related]
16. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo.
Wiemann K; Mittrücker HW; Feger U; Welte SA; Yokoyama WM; Spies T; Rammensee HG; Steinle A
J Immunol; 2005 Jul; 175(2):720-9. PubMed ID: 16002667
[TBL] [Abstract][Full Text] [Related]
17. Human tumor-derived exosomes down-modulate NKG2D expression.
Clayton A; Mitchell JP; Court J; Linnane S; Mason MD; Tabi Z
J Immunol; 2008 Jun; 180(11):7249-58. PubMed ID: 18490724
[TBL] [Abstract][Full Text] [Related]
18. Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells.
Lutz S; Klausz K; Albici AM; Ebinger L; Sellmer L; Teipel H; Frenzel A; Langner A; Winterberg D; Krohn S; Hust M; Schirrmann T; Dübel S; Scherließ R; Humpe A; Gramatzki M; Kellner C; Peipp M
Front Immunol; 2023; 14():1227572. PubMed ID: 37965326
[TBL] [Abstract][Full Text] [Related]
19. NKG2D engagement of colorectal cancer-specific T cells strengthens TCR-mediated antigen stimulation and elicits TCR independent anti-tumor activity.
Maccalli C; Pende D; Castelli C; Mingari MC; Robbins PF; Parmiani G
Eur J Immunol; 2003 Jul; 33(7):2033-43. PubMed ID: 12884870
[TBL] [Abstract][Full Text] [Related]
20. Bispecific T-cell engagers for cancer immunotherapy.
Huehls AM; Coupet TA; Sentman CL
Immunol Cell Biol; 2015 Mar; 93(3):290-6. PubMed ID: 25367186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
